Overview

Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)

Status:
Active, not recruiting

Trial end date:
2022-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to measure the effect of IPI-549 in combination with nivolumab when compared to nivolumab monotherapy in advanced urothelial cancer patients.

Phase:

Phase 2

Details

Lead Sponsor:

Infinity Pharmaceuticals, Inc.

Collaborator:

Bristol-Myers Squibb

Treatments:

Nivolumab